

DAFTAR PUSTAKA

1. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia*. 2006;47(7):1094–120.
2. Bonnett LJ, Smith CT, Donegan S, Marson AG. Treatment outcome after failure of a first antiepileptic drug. *Neurology*. 2014;82(36):553–60.
3. Kovac S, Diehl B. Atonic phenomena in focal seizures: Nomenclature, clinical findings and pathophysiological concepts. *Seizure*. 2012;4(3):561–7.
4. So NK. Atonic phenomena and partial seizures. A reappraisal. *Adv Neurol*. 1995;67:29–39.
5. Oguni H, Fukuyama Y, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, et al. Myoclonic-astatic epilepsy of early childhood - Clinical and EEG analysis of myoclonic-astatic seizures, and discussions on the nosology of the syndrome. *Brain Dev*. 2001;23(7):757–64.
6. Maehara T, Shimizu H. Surgical outcome of corpus callosotomy in patients with drop attacks. *Epilepsia*. 2001;42(1):67–71.
7. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE Official Report: A practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475–82.
8. Matsumoto R, Ikeda A, Ohara S, Kunieda T, Kimura K, Takahashi JB, et al. Nonconvulsive focal inhibitory seizure: Subdural recording from motor cortex. *Neurology*. 2000;55(3):429–31.
9. Ikeda A, Hirasawa KI, Kinoshita M, Hitomi T, Matsumoto R, Mitsueda T, et al. Negative motor seizure arising from the negative motor area: Is it ictal apraxia? *Epilepsia*. 2009;50(9):2072–84.
10. Gilboa T. Emotional stress-induced seizures: Another reflex epilepsy? *Epilepsia*. 2012;53(2):29–32.
11. Enatsu R, Matsumoto R, Piao Z, O'Connor T, Horning K, Burgess RC, et al. Cortical negative motor network in comparison with sensorimotor network: A cortico-cortical evoked potential study. *Cortex*. 2013;49(8):2080–96.
12. Fuhr P, Agostino R, Hallett M. Spinal motor neuron excitability during the silent period after cortical stimulation. *Electroencephalogr Clin Neurophysiol Evoked Potentials*. 1991;81(4):257–62.
13. Ikeda A, Lüders HO, Burgess RC, Shibasaki H. Movement-related potentials recorded from supplementary motor area and primary motor area: Role of supplementary motor area in voluntary movements. *Brain*. 1992;95(5):323–334.

14. Matsumoto R, Ikeda A, Hitomi T, Aoki T, Hanakawa T, Miki Y, et al. Ictal monoparesis associated with lesions in the primary somatosensory area. *Neurology*. 2005;65(9):1476–8.
15. Kovac S, Nachev P, Rodionov R, Scott C, McEvoy AW, Toms N, et al. Neck atonia with a focal stimulation-induced seizure arising from the SMA: Pathophysiological considerations. *Epilepsy Behav*. 2012;24(4):503–6.
16. Zhao J, Afra P, Adamolekun B. Partial epilepsy presenting as focal atonic seizure: A case report. *Seizure*. 2010;19(6):326–9.
17. Satow T, Ikeda A, Yamamoto J, Takayama M, Matsushashi M, Ohara S, et al. Partial epilepsy manifesting atonic seizure: Report of two cases. *Epilepsia*. 2002;43(11):1425–31.
18. Mori S, Iwakiri H, Homma Y, Yokoyama T, Matsuyama K. Neuroanatomical and neurophysiological bases of postural control. *Adv Neurol*. 1995;67:289–303.
19. Benbadis S. The differential diagnosis of epilepsy: A critical review. *Epilepsy Behav*. 2009;15(1):15–21.
20. Itoh Y, Oguni H, Hirano Y, Osawa M. Study of epileptic drop attacks in symptomatic epilepsy of early childhood - Differences from those in myoclonic-astatic epilepsy. *Brain Dev*. 2015;37(1):49–58.
21. Cowan LD. The epidemiology of the epilepsies in children. *Ment Retard Dev Disabil Res Rev*. 2002;8(3):171–81.
22. Bhalla D, Godet B, Druet-Cabanac M, Preux PM. Etiologies of epilepsy: A comprehensive review. *Expert Rev Neurother*. 2011;11(6):861–76.
23. Marcovecchio ML, Petrosino MI, Chiarelli F. Diabetes and Epilepsy in Children and Adolescents. *Curr Diab Rep*. 2015;15(4):21.
24. Ganelin-Cohen E, Modan-Moses D, Hemi R, Kanety H, Ben-zeev B, Hampe CS. Epilepsy and behavioral changes, type 1 diabetes mellitus and a high titer of glutamic acid decarboxylase antibodies. *Pediatr Diabetes*. 2016;17(8):617–22.
25. Dy ABC, Tassone F, Eldeeb M, Salcedo-Arellano MJ, Tartaglia N, Hagerman R. Metformin as targeted treatment in fragile X syndrome. *Clin Genet*. 2018;93(2):216–22.
26. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, et al. Care of children and adolescents with type 1 diabetes: A statement of the American Diabetes Association. *Diabetes Care*. 2005;28(1):186–212.
27. Jose RL Batubara, Bambang Tridjaja AAP ABP. Buku ajar Endokrinologi anak. Buku Ajar Endokrinologi Anak. 2010.
28. Vianna JBM, Atallah AN, Prado GF, Valente O, Duarte-Barros ML, Vianna ECS, et al. The oral glucose tolerance test is frequently abnormal in patients with uncontrolled epilepsy. *Epilepsy Behav*. 2006;9(1):140–4.
29. Shorvon SD. The causes of epilepsy: Changing concepts of etiology of epilepsy over the past 150 years. *Epilepsia*. 2011;52(6):1033–44.

30. Woods RJ, Gruenthal M. Cognition-induced epilepsy associated with specific emotional precipitants. *Epilepsy Behav.* 2006;9(2):360–2.
31. El Bouzidi K, Duncan S, Whittle IR, Butler CR. Lesional reflex epilepsy associated with the thought of food. *Neurology.* 2010;74(7):610–2.
32. Zifkin BG, Trenite DKN. Reflex epilepsy and reflex seizures of the visual system: A clinical review. *Epileptic Disord.* 2000;2(3):129–36.
33. Zifkin BG, Inoue Y. Visual Reflex Seizures Induced by Complex Stimuli. *Epilepsia.* 2004;45(Suppl 1):27–9.
34. Salek-Haddadi Afraim, Mayer T, K H, Symms M, Josephs O, Fluegel D, et al. Imaging seizure activity: a combined EEG/EMG-fMRI study in reading epilepsy. *Epilepsia.* 2009;50(2):256–64.
35. Aguglia U, Le Piane E, Gambardella A, Messina D, Russo C, Sirchia SM, et al. Emotion-induced myoclonic absence-like seizures in a patient with inv- dup(15) syndrome: A clinical, EEG, and molecular genetic study. *Epilepsia.* 1999;40(9):1316–9.
36. Battaglia A. The inv dup(15) or idic(15) syndrome: A clinically recognisable neurogenetic disorder. *Brain Dev.* 2005;27(5):365–9.
37. Battaglia A. The inv dup (15) or idic (15) syndrome (Tetrasomy 15q). *Orphanet J Rare Dis.* 2008;3(30):1–7.
38. Chifari R, Guerrini R, Pierluigi M, Cavani S, Sgrò V, Elia M, et al. Mild generalized epilepsy and developmental disorder associated with large inv dup(15). *Epilepsia.* 2002;43(9):1096–100.
39. Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH. Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11-q13). *Hum Mol Genet.* 1999;8(6):1025–7.
40. Robinson WP, Binkert F, Gine R, Vazquez C, Muller W, Rosenkranz W, et al. Clinical and molecular analysis of five inv dup(15) patients. *Eur J Hum Genet.* 1993;1(1):37–50.
41. Makoff AJ, Flomen RH. Detailed analysis of 15q11-q14 sequence corrects errors and gaps in the public access sequence to fully reveal large segmental duplications at breakpoints for Prader-Willi, Angelman, and inv dup(15) syndromes. *Genome Biol.* 2007;129(1):247–55.
42. De Vries BBA, Wiegers AM, Smits APT, Mohkamsing S, Duivenvoorden HJ, Fryns J-P, et al. Mental Status of Females with an FMR1 Gene Full Mutation. *Am J Hum Genet.* 1996;32(5):277–83.
43. Hantash FM, Goos DG, Tsao D, Quan F, Buller-Burckle A, Peng M, et al. Qualitative assessment of fmrl (CGG)_n triplet repeat status in normal, intermediate, premutation, full mutation, and mosaic carriers in both sexes: Implications for fragile x syndrome carrier and newborn screening. *Genet Med.* 2010;12(3):162–73.
44. Garber K, Smith KT, Reines D, Warren ST. Transcription, translation and fragile X syndrome. *Curr Opin Genet Dev.* 2006;16(3):270–5.

45. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med.* 2013;15(3):399–407.
46. Jacobs PA, Glover TW, Mayer M, Fox P, Gerrard JW, Dunn HG, et al. X-linked mental retardation: A study of 7 families. *Am J Med Genet.* 1980;7(4):471–89.
47. Wilson MG, Marchese CA. Prenatal diagnosis of fragile X in a heterozygous female fetus and postnatal follow-up. *Prenat Diagn.* 1984;4(1):61–6.
48. Lozano R, Azarang A, Wilaisakditipakorn T, Hagerman RJ. Fragile X syndrome: A review of clinical management. *Intractable Rare Dis Res.* 2016;5(3):145–57.
49. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, et al. Fragile X syndrome. *Nat Rev Dis Prim.* 2017;3:17065.
50. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The Diagnosis and Management of Acute Otitis Media. *Pediatrics.* 2013;131(3):e964–99.
51. Incorpora G, Sorge G, Sorge A, Pavone L. Epilepsy in fragile X syndrome. *Brain Dev.* 2002;24(8):766–9.
52. Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK, et al. Valproic acid pathway: Pharmacokinetics and pharmacodynamics. *Pharmacogenet Genomics.* 2013;23(4):236–41.
53. Crabbe L, Hornstein L, Bensky A, Schwartz D. Cardiovascular Abnormalities in Children With Fragile X Syndrome. *Pediatrics.* 1993;109((50)):E3434–43.
54. Loehr JP, Synhorst DP, Wolfe RR, Hagerman RJ. Aortic root dilatation and mitral valve prolapse in the fragile X syndrome. *Am J Med Genet.* 1986;23(1–2):189–94.
55. Goldson E, Hagerman RJ. Fragile X Syndrome and Failure to Thrive. *Am J Dis Child.* 1993;147(6):242–52.
56. Kronk R, Bishop EE, Raspa M, Bickel JO, Mandel DA, Bailey DB. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. *Sleep.* 2010;33(5):679–87.
57. Owens JA, Spirito A, Mcguinn M. The Children’s Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. *Sleep.* 2000;23(8):1043–51.
58. Wirojatanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. *J Clin Sleep Med.* 2009;15(2):145–50.
59. Wrenn CC, Heitzer AM, Roth AK, Nawrocki L, Valdovinos MG. Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice. *Neurosci Lett.* 2015;12(585):109–13.
60. Skinner HJ, Walther RB, Dolwick MF, Berry RB, Wagner MH. Management of obstructive sleep apnea in a developmentally delayed pediatric patient with aggressive behavior and pierre robin sequence. *J Clin Sleep Med.* 2015;11(2):181–3.

61. Hatton DD, Buckley E, Lachiewicz A, Roberts J. Ocular status of boys with fragile X syndrome: A prospective study. *J AAPOS*. 1998;2(5):298–302.
62. Alanay Y, Ünal F, Turanlı G, Alikasıfoğlu M, Alehan D, Akyol U, et al. A multidisciplinary approach to the management of individuals with fragile X syndrome. *J Intellect Disabil Res*. 2007;51(2):151–61.
63. Repka MX, Friedman DS, Katz J, Ibrionke J, Giordano L, Tielsch JM. The prevalence of ocular structural disorders and nystagmus among preschool-aged children. *J AAPOS*. 2012;16(2):182–4.
64. Hersh JH, Saul RA. Health Supervision for Children With Fragile X Syndrome. *Pediatrics*. 2011;127(5):994–1006.
65. Schneider SA, Robertson MM, Rizzo R, Turk J, Bhatia KP, Orth M. Fragile X syndrome associated with Tic disorders. *Mov Disord*. 2008;23(8):1108–12.
66. Jankovic J. Phenomenology and classification of tics. *Neurol Clin*. 1997;99:1–16.
67. Oguni H, Imaizumi Y, Uehara T, Oguni M, Fukuyama Y. Electroencephalographic features of epileptic drop attacks and absence seizures: a case study. *Brain Dev*. 1993;15(3):226–30.
68. Cuthill FM, Espie CA. Sensitivity and specificity of procedures for the differential diagnosis of epileptic and non-epileptic seizures: A systematic review. *Seizure*. 2005;14(5):293–303.
69. Camacho A, Simón R, Sanz R, Viñuela A, Martínez-Salio A, Mateos F. Cognitive and behavioral profile in females with epilepsy with PDCH19 mutation: Two novel mutations and review of the literature. *Epilepsy Behav* [Internet]. 2012;24(1):134–7. Available from: <http://dx.doi.org/10.1016/j.yebeh.2012.02.023>
70. Egger J. Lesson of the week: Benign sleep myoclonus in infancy mistaken for epilepsy. *BMJ (Clinical Res ed)*. 2003;326(7396):975–6.
71. Lutas A, Yellen G. The ketogenic diet: Metabolic influences on brain excitability and epilepsy. *Trends Neurosci*. 2013;36(1):32–40.
72. Nangia S, Caraballo RH, Kang HC, Nordli DR, Scheffer IE. Is the ketogenic diet effective in specific epilepsy syndromes? *Epilepsy Res*. 2012;100(3):252–7.
73. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. *Lancet Neurol*. 2008;7(6):500–6.
74. Bonaz B, Picq C, Sinniger V, Mayol JF, Clarençon D. Vagus nerve stimulation: From epilepsy to the cholinergic anti-inflammatory pathway. *Neurogastroenterol Motil*. 2013;25(3):208–21.
75. Lundgren T, Dahl J, Melin L, Kies B. Evaluation of acceptance and commitment therapy for drug refractory epilepsy: A randomized controlled trial in South Africa - A pilot study. *Epilepsia*. 2006;47(12):2173–9.
76. Mehndiratta P, Sajatovic M. Treatments for patients with comorbid epilepsy and

- depression: A systematic literature review. *Epilepsy Behav.* 2013;28(1):36–40.
77. Bujoreanu IS, Ibeziako P, DeMaso DR. Psychiatric Concerns in Pediatric Epilepsy. *Pediatr Clin North Am.* 2011;58(4):973–88.
 78. Jonsson P, Eeg-Olofsson O. 10-Year outcome of childhood epilepsy in well-functioning children and adolescents. *Eur J Paediatr Neurol.* 2011;15(4):331–7.
 79. Zafeiriou DI, Kontopoulos EE, Tsikoulas I. Characteristics and prognosis of epilepsy in children with cerebral palsy. *J Child Neurol.* 1999;14(5):289–94.
 80. Hogart A, Wu D, LaSalle JM, Schanen NC. The comorbidity of autism with the genomic disorders of chromosome 15q11.2-q13. *Neurobiol Dis.* 2010;38(2):181–91.
 81. Nurputra DK, Nakagawa T, Takeshima Y, Harahap ISK, Morikawa S, Sakaeda T, et al. Paramyotonia congenita: From clinical diagnosis to in silico protein modeling analysis. *Pediatr Int.* 2012;54(5):602–12.
 82. Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome-features, mechanisms and management. *Nat Rev Neurol.* 2016;12:403–412.
 83. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder. *Pediatrics.* 2009;124(6):1533–40.
 84. Lenze EJ, Mulsant BH, Blumberger DM, Karp JF, Newcomer JW, Anderson SJ, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: A randomised, double-blind, placebo-controlled trial. *Lancet.* 2015;386(10011):2404–12.
 85. Bodnar M, Malla AK, Makowski C, Chakravarty MM, Joobar R, Lepage M. The effect of second-generation antipsychotics on hippocampal volume in first episode of psychosis: longitudinal study. *Br J Psychiatry Open.* 2016;2(2):139–46.
 86. Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, et al. Metabolic side effects of risperidone in early onset schizophrenia. *Encephale.* 2010;36(3):242–52.
 87. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. *Schizophr Res.* 1999;35(1):51–68.
 88. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. *J Am Med Assoc.* 2002;288(19):2469–75.
 89. Von Korff M, Gruman J, Schaefer J, Curry SJ, Wagner EH. Collaborative management of chronic illness. *Ann Intern Med.* 1997;127(12):1097–102.
 90. Weisz ED, Towheed A, Monyak RE, Toth MS, Wallace DC, Jongens TA. Loss of *Drosophila* FMRP leads to alterations in energy metabolism and mitochondrial function. *Hum Mol Genet.* 2018;27(1):95–106.
 91. Raspa M, Bailey DB, Bishop E, Holiday D, Olmsted M. Obesity, food selectivity, and physical activity in individuals with fragile X syndrome. *Am J Intellect Dev Disabil.*

92. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;
93. Wheeler AC, Skinner DG, Bailey DB. Perceived quality of life in mothers of children with fragile X syndrome. Am J Ment Retard. 2008;113(3):159–77.
94. Chevreul K, Berg Brigham K, Brunn M, des Portes V, Serrano-Aguilar P, Linertová R, et al. Fragile X syndrome: Economic burden and health-related quality of life of patients and caregivers in France. J Intellect Disabil Res. 2015;59(12):1108–20.